Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: A randomized, double-blind, placebo-controlled trial

Diabetes Technology and Therapeutics

Volumn 16, Issue 10, 2014, Pages 679-687

  Klein, David J ^a   Battelino, T ^f   Chatterjee, D J ^c   Jacobsen, Lisbeth V ^d   Hale, Paula M ^c   Arslanian, Silva ^e,f   De Schepper, J ^f   Barrett, T ^f   Bone, M ^f   Randel, T ^f   Blumer, J ^f   Christensen, M ^f   Ferry, R ^f   Hazan, L ^f   Klein, D J ^f   Lopez, X ^f   Neufeld, N ^f   Toltzis, P ^f   Tsalikian, E ^f   Wadwa, R P ^f   Wintergerst, K ^f   more..

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^c NOVO NORDISK INC   (United States)

^d NOVO NORDISK A S   (Denmark)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; CALCITONIN; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PLACEBO; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABDOMINAL PAIN; ADOLESCENT; AMYLASE BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; CALCITONIN BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KINESIOTHERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; ANALOGS AND DERIVATIVES; BELGIUM; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MULTICENTER STUDY; ONSET AGE; PEDIATRIC OBESITY; PREVALENCE; SLOVENIA; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; WEIGHT REDUCTION;

ADOLESCENT; AGE OF ONSET; BELGIUM; BLOOD GLUCOSE; BODY WEIGHT; CHILD; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GLUCAGON-LIKE PEPTIDE 1; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PEDIATRIC OBESITY; PREVALENCE; SLOVENIA; TREATMENT OUTCOME; UNITED STATES; WEIGHT LOSS;

EID: 84907519425     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0366     Document Type: Article

References (41)

1. Pinhas-Hamiel O, Zeitler P: The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005;146:693-700.
2. International Diabetes Federation: Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. 2011. www.idf.org/sites/default/files/Diabetes-in-Childhoodand-Adolescence-Guidelines.pdf (accessed February 10, 2014).
3. Zeitler P, Hirst K, Pyle L, et al.: A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247-2256.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al.:Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
5. Copeland KC, Silverstein J, Moore KR, et al.: Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics 2013;131:364-382.
6. Novo Nordisk A/S: Victoza-(Liraglutide) Summary of Product Characteristics. www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001026/WC500050017.pdf (accessed February 10, 2014).
7. Novo Nordisk, Inc.: Victoza-(Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use [Prescribing Information]. Princeton, NJ: Novo Nordisk, Inc., 2012. www .accessdata.fda.gov/drugsatfda-docs/label/2012/022341s017lbl .pdf (accessed February 10, 2014).
8. Garber A, Henry R, Ratner R, et al.: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
9. Pratley RE, Nauck M, Bailey T, et al.: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456.
10. Marre M, Shaw J, Brandle M, et al.: Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278.
11. Nauck M, Frid A, Hermansen K, et al.: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90.
12. Russell-Jones D, Vaag A, Schmitz O, et al.: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009;52:2046-2055.
13. Buse JB, Rosenstock J, Sesti G, et al.: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
14. Zinman B, Gerich J, Buse JB, et al.: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009;32:1224-1230.
15. Novo Nordisk: Victoza-US Prescribing Information 2013. https://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022341lbl.pdf (accessed February 10, 2014).
16. Blonde L, Russell-Jones D: The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009;11(Suppl 3):26-34.
17. Horowitz M, Flint A, Jones KL, et al.: Effect of the oncedaily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012;97:258-266.
18. van Can J, Sloth B, Jensen CB, et al.: Effects of liraglutide on appetite, ad libitum energy intake, 24-hour energy expenditure and substrate oxidation in obese non-diabetic adults: a randomized, placebo-controlled, incomplete crossover trial [abstract]. Obesity 2012 30th Annual Scientific Meeting. 2012:259-P. www.obesity.org/images/stories/obesity2012/2012-Abstracts.pdf (accessed February 10, 2014).
19. Elbrond B, Jakobsen G, Larsen S, et al.: Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25: 1398-1404.
20. Jiang J, Zhang J, Jacobsen LV, et al.: The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. J Clin Pharmacol 2011;51:1620-1627.
21. Agerso H, Jensen LB, Elbrond B, et al.: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.
22. Damholt B, Golor G, Wierich W, et al.: An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagonlike peptide-1 analogue liraglutide. J Clin Pharmacol 2006;46: 635-641.
23. Irie S, Matsumura Y, Zdravkovic M, et al.: Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther 2008;46:273-279.
24. Ingwersen SH, Khurana M, Madabushi R, et al.: Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol 2012;52: 1815-1823.
25. Centers for Disease Control and Prevention: National Diabetes Fact Sheet. 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf (accessed January 29, 2014).
26. Dabelea D, Bell RA, D'Agostino RB Jr, et al.: Incidence of diabetes in youth in the United States. JAMA 2007;297: 2716-2724.
27. European Union Commission: Communication from the Commission-guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies 2008/C 243/01. Official Journal of the European Union Information and Notices C 2008;51(243):1-12. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri = OJ:C:2008:243:0001:0012:EN:PDF (accessed January 29, 2014).
28. European Medicines Agency: P/0122/2012: EMA Decision of 4 July 2012 on the Acceptance of a Modification of an Agreed Paediatric Investigation Plan for Liraglutide (Victoza) (EMEA-000128-PIP01-07-M04). 2012. www.ema .europa.eu/ema/index.jsp?curl = pages/medicines/pips/EMEA-000128-PIP01-07-M04/pip-000270.jsp&mid = WC0b01ac 058001d129 (accessed January 29, 2014).
29. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249.
30. Novo Nordisk: Efficacy and Safety of Liraglutide in Combination with Metformin Compared to Metformin Alone, in Children and Adolescents with Type 2 Diabetes. NCT01541215. clinicaltrials.gov/ct2/show/NCT01541215 (accessed January 29, 2014).
31. Olansky L: Do incretin-based therapies cause acute pancreatitis? J Diabetes Sci Technol 2010;4:228-229.
32. Steinberg WM, DeVries JH, Wadden T, et al.: Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglutide [abstract Tu1502]. Gastroenterology 2012;142(5 Suppl 1):S850-S851.
33. Petri KC, Jacobsen LV, Ingwersen SH, et al.: Liraglutide in paediatric subjects with type 2 diabetes: a population pharmacokinetic (PK) analysis and comparison to adult subjects [abstract]. Diabetologia 2012;55(Suppl 1):S332.
34. Merck & Co.: A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081). NCT00730275. http://clinicaltrials.gov/ct2/show/NCT00730275 (accessed January 29, 2014).
35. Malloy J, Capparelli E, Gottschalk M, et al.: Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, singleblind, dose-escalation, crossover study. Clin Ther 2009;31: 806-815.
36. Amylin Pharmaceuticals, LLC: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes. NCT00658021. http://clinicaltrials.gov/ct2/show/NCT00658021 (accessed January 29, 2014).
37. Amylin Pharmaceuticals, LLC: Safety and Efficacy Study of Exenatide Once Weekly in Adolescents with Type 2 Diabetes. NCT01554618. http://clinicaltrials.gov/show/NCT01554618 (accessed January 29, 2014).
38. Merck & Co.: Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1). NCT01485614. http://clinicaltrials.gov/show/NCT01485614 (accessed January 29, 2014).
39. Merck & Co.: A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants with Type 2 Diabetes Mellitus (MK-0431A-170 AM1). NCT01472367. http://clinicaltrials.gov/show/NCT01472367 (accessed January 29, 2014).
40. Bristol-Myers Squibb: Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients with Type 2 Diabetes. NCT01204775. http://clinicaltrials.gov/show/NCT01204775 (accessed January 29, 2014).
41. Gemmill JA, Brown RJ, Nandagopal R, et al.: Clinical trials in youth with type 2 diabetes. Pediatr Diabetes 2011; 12:50-57.